Efficacy Study of Integrated TCM Combined With Chemotherapy in Postoperative NSCLC Patients

• ClinicalTrials.gov Identifier: NCT01441752
• Recruitment Status: Completed
• First Posted: September 28, 2011
• Last Update Posted: June 27, 2016
• Sponsor: xuling
• Information provided by (Responsible Party): xuling, Shanghai University of Traditional Chinese Medicine

Study Description

Brief Summary:

The investigators performed a multi-center, randomized, controlled, double-blind, prospective study on evaluating effect of chemotherapy combined with or without integrated TCM on quality of life (QOL) of postoperative Non-small Cell Lung Cancer (NSCLC) patients. The investigators plan to involve 600 cases for observation in 3 years (300 cases for each group), expecting that QOL of postoperative NSCLC patients can be improved by integrated TCM combined with chemotherapy compared to that by chemotherapy alone.

Condition or disease	Intervention/treatment	Phase
Non-small Cell Lung Cancer	Drug: TCM; Drug: placebo	Phase 3

Detailed Description:

At present the high rate of recurrence and metastasis of postoperative non-small cell lung cancer (NSCLC) patients is one of the leading causes resulting in failure of treating lung cancer. More than 35% of postoperative lung cancer patients with stage I died in 5 years due to recurrence or metastasis; the 5-year survival rates of stage II, IIIa, IIIb were 31%, 17.9% and 11.7% respectively. The survival rate was improved by 5% with adjuvant chemotherapy after resection, so regimen consist of platinum-based two chemical medicines are commended as the adjuvant chemotherapy for treating postoperative NSCLC patients, but the toxicity and side effects of chemotherapy can decrease quality of life (QOL) of patients. Literature and our preliminary studies have shown that traditional Chinese medicine (TCM) can prolong survival and improve QOL, but high-level evidences are needed.

The investigators perform a randomized, double-blind study in NSCLC patients after complete resection with stage I-III. Patients are randomized over observational group (TCM granules plus chemotherapy), and control group (TCM placebo plus chemotherapy). The investigators will observe 4 treatment periods, after that the observational group will be treated for another 4 months with integrated TCM combined with western medicine treatment (oral TCM medicines plus TCM intravenous injections), and there is no intervene measures in control group. Regular follow-up will be arranged. The primary efficacy assessments are: QOL (QLQ-C30 scales); Secondary efficacy assessments are: (1) 2-year disease-free survival rate; (2) disease-free survival; other efficacy assessments are: (1) TCM symptoms changes; (2) tumor markers (CEA, CA-125 and CYFRA21-1) and so on. Toxicity, side effects and security of the treatments will be assessed at the same time. The investigators expect that integrated TCM combined with Western medicine treatment has a better efficacy on improving QOL of patients, prolonging disease-free survival time than that of chemotherapy treatment. Therefore our study can provide evidences for optimizing and promoting integrated TCM combined with Western Medicine treatment.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 349 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: State Administration of Traditional Chinese Medicine of Shanghai
• Study Start Date: November 2011
• Actual Primary Completion Date: March 2015
• Actual Study Completion Date: March 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Chemotherapy + TCM group; The chemotherapy for NSCLC patients is a combination of Vinorelbine, 25mg/m2, d1, 8 and DDP, 75mg/m2, d1 (NP) giving three-weekly for four cycles. Prescriptions formulated into granules origin from Professor Liu Jiaxiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe . Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.	Drug: TCM; three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.; Other Name: Prescriptions from Professor Liu Jiaxiang
Placebo Comparator: Chemotherapy + placebo group; The chemotherapy for NSCLC patients is a combination of Vinorelbine, 25mg/m2, d1, 8 and DDP, 75mg/m2, d1 (NP) giving three-weekly for four cycles.we compromise the raw materials for the placebo including 10% of Chinese medicine, food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages.	Drug: placebo; three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell ，taste weight and package

Outcome Measures

Primary Outcome Measures :

1. quality of life（QoL) [ Time Frame: every three weeks ]

Secondary Outcome Measures :

1. two-year disease-free survival rate and disease-free survival [ Time Frame: once every three months ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Meet the diagnostic criteria of primary bronchial lung cancer, and pathologically or cytologically confirmed of NSCLC (squamouscarcinoma, adenocarcinoma, adenosquamous carcinoma and large cell carcinoma) patients;
2. Age > 18 years old;
3. TCM syndromes are Yin deficiency, Qi deficiency, deficiency of both Qi and Yin, deficiency of both Spleen and Kidney;
4. Physical status score (ECOG PS) ≤ 2 scores;
5. Stage Ib ~ Ⅲb with complete resection, chemotherapy is performed in 6 weeks after resection, including tumor size > 2cm of stage Ia;
6. Blood routine: N > 1.5×109/L、PLT > 100×109/L, normal liver function and kidney function;
7. Voluntarily involved to clinical study and sign informed consent.

Exclusion Criteria:

1. Suffering from other primary malignant tumor in 5 years;
2. Incomplete resection or uncertain to take resection;
3. Serious disease of heart, liver, kidney with severe dysfunction;
4. Pregnancy or breast-feeding women;
5. Mental or cognitive disorders which would influence judgment of QOL in this study;
6. During or had adjuvant chemotherapy;
7. Being participating other drug trials;
8. Allergy to the drug in our study.

Contacts and Locations

Locations

China, Shanghai

ShanghaiUTCM

Shanghai, Shanghai, China, 200032

Xuling

Shanghai, Shanghai, China, 200032

Sponsors and Collaborators

xuling

Investigators

• Principal Investigator: xu ling; Shanghai University of Traditional Chinese Medicine
• Principal Investigator: xu ling, doctor; Shanghai University of Traditional Chinese Medicine

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Wang Q, Jiao L, Wang S, Chen P, Bi L, Zhou D, Yao J, Li J, Wang L, Chen Z, Jia Y, Zhang Z, Shen W, Zhu W, Xu J, Gao Y, Xu L, Gong Y. Adjuvant Chemotherapy with Chinese Herbal Medicine Formulas Versus Placebo in Patients with Lung Adenocarcinoma after Radical Surgery: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Biol Proced Online. 2020 Mar 1;22:5. doi: 10.1186/s12575-020-00117-5. eCollection 2020.

Xu L, Li H, Xu Z, Wang Z, Liu L, Tian J, Sun J, Zhou L, Yao Y, Jiao L, Su W, Guo H, Chen P, Liu J. Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients. BMC Complement Altern Med. 2012 Aug 1;12:112. doi: 10.1186/1472-6882-12-112.

• Responsible Party: xuling, State Administration of Traditional Chinese Medicine of Shanghai, Shanghai University of Traditional Chinese Medicine
• ClinicalTrials.gov Identifier: NCT01441752
• Other Study ID Numbers: LC 001
• First Posted: September 28, 2011
• Last Update Posted: June 27, 2016
• Last Verified: June 2016

Additional relevant MeSH terms:

Carcinoma, Non-Small-Cell Lung; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases